Characterising acquired resistance to erlotinib in non-small cell lung cancer patients-Reference-Cited by-同舟云学术

Characterising acquired resistance to erlotinib in non-small cell lung cancer patients

Published:2019-08-19 Issue:10 Volume:13 Page:1019-1028
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Karachaliou Niki¹,Codony-Servat Jordi²,Bracht Jillian Wilhelmina Paulina²,Ito Masaoki²,Filipska Martyna³,Pedraz Carlos³,Chaib Imane³,Bertran-Alamillo Jordi²,Cardona Andres Felipe⁴,Molina Miguel Angel²,Rosell Rafael²³⁵⁶

Affiliation:

1. Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany

2. Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute, Barcelona, Spain

3. Cancer Biology and Precision Medicine, Institut d’Investigació en Ciències Germans Trias i Pujol, Badalona, Spain

4. Thoracic Oncology Unit, Clinical and Translational Oncology Group, Clinica del Country, Bogotá, Colombia

5. Institute of Oncology Rosell (IOR), Quiron-Dexeus University Institute, Barcelona, Spain

6. Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2019.1656068

Reference100 articles.

1. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

2. EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients

3. Optimizing lung cancer treatment approaches

4. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis;MedComm;2024-07-20

2. Advancements in NSCLC;American Journal of Clinical Oncology;2024-02-20

3. Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells;Cell Death Discovery;2024-01-04

4. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials;Journal of Clinical Pharmacy and Therapeutics;2024-01

5. Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells;2023-10-06